Investment in Revolymer Ltd

IP2IPO Group PLC 08 February 2006 For immediate release 8th February 2006 IP2IPO GROUP PLC Revolymer Limited receives funding from IP2IPO IP2IPO Group plc (AIM: IPO) ('IP2IPO') is pleased to announce that it has invested £500,000 and has received a 40 % equity interest in Revolymer Limited ('Revolymer'), a spin-out company from the Chemistry Department at the University of Bristol. Revolymer is focused on developing new polymers with enhanced physical properties manufactured from existing commodity polymers. Revolymer's novel materials have potential applications in a number of markets including non-stick gums, medical devices, paints and coatings and personal health care products and Revolymer is in detailed discussions to establish commercial partnerships in the near term. Revolymer's management team is lead by CEO Roger Pettman who was co-founder of ChiRex which he took from formation to an IPO on NASDAQ prior to its sale to Rhodia in 2000. IP2IPO's stake in Revolymer is comprised of a 13.3% interest received as a result of its long-term agreement with the University of Bristol and a 27.7 % interest acquired as a result of a direct investment. The investment made by IP2IPO was part of a £750,000 financing with additional investment from the SULIS Seedorn Fund. Commenting on today's announcement, Alan Aubrey, IP2IPO's Chief Executive, said: 'We are very pleased to be completing IP2IPO's first investment from Bristol two months after establishing the partnership. Revolymer represents a very exciting investment for IP2IPO with exceptional technology addressing potentially very large markets and backed by a strong management team.' For more information please contact: IP2IPO 020 7489 5200 Alan Aubrey, Chief Executive Officer Buchanan Communications 020 7466 5000 Tim Anderson, Mark Court, Mary-Jane Johnson Notes for editors IP2IPO is an intellectual property (IP) company that specialises in commercialising university technology. The Company was founded in 2001 and listed on the AIM Market of the London Stock Exchange plc in October 2003. IP2IPO's first partnership was with the University of Oxford. In return for an investment of £20 million, IP2IPO has acquired 50 per cent of the University of Oxford's equity in spin-out companies and technology licenses based on intellectual property created at the Chemistry Department until 2015. In November 2003, IP2IPO created a £5 million seed capital fund for investing in spin-out companies across the University of Oxford, not just those originating within the Chemistry Department. In March 2002, IP2IPO entered into a second long-term partnership with the University of Southampton. Under the terms of this partnership, IP2IPO is committed to working with the University of Southampton in the identification and facilitation of spin-out companies from across the University of Southampton and to investing £5 million in early-stage University of Southampton spin-out companies over a four year period in return for equity stakes in those companies. In addition, IP2IPO also received a 20 per cent stake in Southampton Asset Management Limited, a company that has been formed to hold the University's equity stakes in its spin-out companies. The partnership has a term of at least 25 years. IP2IPO entered into its third long-term partnership in May 2003 with King's College London. IP2IPO works with King's College London to help identify and progress commercialisation opportunities as well as invest £5 million in seed capital in spin-out companies from King's College London over a five year period in return for equity stakes in those companies. In addition, IP2IPO receives 20 per cent of King's College London's equity in spin-out companies and technology licenses. The partnership has a term of 25 years. In October 2003, IP2IPO announced a fourth partnership with the Centre for Novel Agricultural Products ('CNAP'), based at the University of York. CNAP is a flagship research centre that specialises in plant and microbial gene discovery. Under the terms of the partnership a new company, Amaethon Limited, has been created which has the right to commercialise CNAP's IP for 25 years. IP2IPO has invested £1.15m in Amaethon Limited in return for a 40% equity stake in Amaethon Limited (the remaining equity being owned by the University of York) and will also invest in the spin-out companies based on CNAP's IP which Amaethon Limited creates. In June 2004, IP2IPO acquired Top Technology Ventures Limited, an investment adviser to early stage technology funds. This combines IP2IPO's expertise in the creation of new ventures based on world leading university IP with Top Technology's focus on making early stage venture capital investments. In January 2005, IP2IPO acquired Techtran, a company set up in 2002 to commercialise university intellectual property under a long-term technology commercialisation contract with the University of Leeds. Under the terms of the contract Techtran receives a significant (30%) interest in spin-out companies created and technology licences negotiated, in return for the provision of technology transfer services to the University. In May 2005, IP2IPO announced the launch of LifeUK, a new subsidiary company. LifeUK, which has since been renamed Modern Biosciences, will in-license life science intellectual property created by medical researchers at universities with which IP2IPO already has partnerships, other universities in the UK and similar academic and charitable research institutions. Modern Biosciences' objective is to further develop the intellectual property which it in-licenses with a view to creating substantial value either by subsequently licensing these development programmes to the pharmaceutical industry or via the creation of new ventures. In December 2005, IP2IPO entered into its sixth long-term partnership with the University of Bristol. IP2IPO will work with the University of Bristol to help identify and progress commercialisation opportunities as well as invest an initial £5 million in seed capital in spin-out companies from the University of Bristol over a five year period in return for equity stakes in those companies. In addition, IP2IPO will receive 13.3% per cent of in spin-out companies at the time that the company is established prior to investment. The partnership has a term of 25 years. To date, 5 spin-out companies from the IP2IPO portfolio have listed on the AIM Market of the London Stock Exchange plc: Offshore Hydrocarbon Mapping plc, Synairgen plc, VASTox plc, Proximagen Neuroscience plc and GETECH Group plc. There has been one trade sale: Toumaz Technology Limited was sold to Nanoscience Inc. This information is provided by RNS The company news service from the London Stock Exchange

Companies

IP Group (IPO)
UK 100

Latest directors dealings